Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Andrea VIngiani"'
Autor:
Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti, Loris De Cecco, Cinzia De Marco, Marco Silvestri, Maria Carmen De Santis, Andrea Vingiani, Biagio Paolini, Rosaria Orlandi, Marilena Valeria Iorio, Giancarlo Pruneri, Paolo Verderio
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is comp
Externí odkaz:
https://doaj.org/article/d7df224a01ee4e5988733bfc39acbfb0
Autor:
Jacopo Azzollini, Luca Agnelli, Elena Conca, Tommaso Torelli, Adele Busico, Iolanda Capone, Marta Angelini, Elena Tamborini, Federica Perrone, Andrea Vingiani, Daniele Lorenzini, Bernard Peissel, Giancarlo Pruneri, Siranoush Manoukian
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Tumour DNA sequencing is essential for precision medicine since it guides therapeutic decisions but also fosters the identification of patients who may benefit from germline testing. Notwithstanding, the tumour-to-germline testing workflow p
Externí odkaz:
https://doaj.org/article/1201518e80a843888ac0f10a86f7d812
Autor:
Nerina Denaro, Lisa Licitra, Marco Merlano, Francesco Perri, Paolo Bossi, Cristina Gurizzan, Federica Perrone, Athanassios Argiris, Loris De Cecco, Stefano Cavalieri, Mara Serena Serafini, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Andrea Vingiani, Maria Grazia Ghi, Alessandra Cassano, Giacomo Allegrini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and h
Externí odkaz:
https://doaj.org/article/b9740be0719d4304a7e872232992bfd0
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683
Autor:
Cristiana Bergamini, Stefano Cavalieri, Carlo Resteghini, Salvatore Alfieri, Imperia Nuzzolese, Elena Colombo, Arianna Ottini, Giuseppina Calareso, Andrea Vingiani, Nicola Alessandro Iacovelli, Marzia Franceschini, Marco Guzzo, Alberto Deganello, Lisa Licitra
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundPregnancy-associated cancer (PAC) occurs during pregnancy or within 12 months after the delivery. Head and neck cancer (HNC) during pregnancy is infrequent, therefore diagnosis and personalized therapy are intricate.MethodsWe investigated o
Externí odkaz:
https://doaj.org/article/3c0265d23df34bdd80d73b247c7d4688
Autor:
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 pat
Externí odkaz:
https://doaj.org/article/1b8f8d9603654e7590deb24e3d8b863d
Autor:
Iolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, Paolo Verderio, Elena Conca, Adele Busico, Maria Adele Testi, Valentina Monti, Matteo Duca, Claudia Proto, Silvia Damian, Alberta Piccolo, Federica Perrone, Elena Tamborini, Andrea Devecchi, Paola Collini, Daniele Lorenzini, Andrea Vingiani, Luca Agnelli, Giancarlo Pruneri
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 5, Pp 582-597 (2022)
Aim: Diagnostic laboratories are progressively introducing next-generation sequencing (NGS) technologies in the routine workflow to meet the increasing clinical need for comprehensive molecular characterization in cancer patients for diagnosis and pr
Externí odkaz:
https://doaj.org/article/d74b17c328cc45588837b22f3835282c
Autor:
Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini, Ruggero De Maria
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-5 (2022)
Abstract Background Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the comparative analysis of MTB
Externí odkaz:
https://doaj.org/article/84b8b9ca44364bdc9a492d814dd3d47c
Autor:
Monica Niger, Federico Nichetti, Andrea Casadei‐Gardini, Federica Morano, Chiara Pircher, Elena Tamborini, Federica Perrone, Matteo Canale, Daniel B. Lipka, Andrea Vingiani, Luca Agnelli, Anna Dobberkau, Jennifer Hüllein, Felix Korell, Christoph E. Heilig, Sara Pusceddu, Francesca Corti, Michele Droz, Paola Ulivi, Michele Prisciandaro, Maria Antista, Marta Bini, Laura Cattaneo, Massimo Milione, Hanno Glimm, Bruno C. Köhler, Giancarlo Pruneri, Daniel Hübschmann, Stefan Fröhling, Vincenzo Mazzaferro, Filippo Pietrantonio, Maria Di Bartolomeo, Filippo deBraud
Publikováno v:
Molecular Oncology, Vol 16, Iss 14, Pp 2733-2746 (2022)
Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, an
Externí odkaz:
https://doaj.org/article/3b4516fdda224755a9583e4ef6af9f00
Autor:
Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli, Andrea Vingiani, Edda Lucia Simoncini, Giancarlo Pruneri, Elisabetta Munzone, Giampaolo Bianchini, Alberto Zambelli, Carlo Tondini
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The increasing understanding of breast cancer biology has provided the basis for the development of multigene signatures aimed to improve the capability of clinicians to assess patients’ prognostication and risk stratification. Incorporating these
Externí odkaz:
https://doaj.org/article/6a67d1afaa084dd89c84e592f33d434c